Health Catalyst (NASDAQ:HCAT) Price Target Cut to $2.00 by Analysts at Citigroup
Citigroup has reduced its price target for Health Catalyst (NASDAQ:HCAT) from $2.50 to $2.00, while maintaining a "neutral" rating, indicating a potential 12% upside from its previous close. Despite beating quarterly EPS and revenue estimates, the company continues to report substantial losses, and analysts …